Introduction
============

Randomized controlled trials (RCTs) have demonstrated that statins are effective for primary and secondary stroke prevention, and the benefit of statins might be largely driven by lipid-lowering effect. Beyond lipid-lowering effect, experimental studies have shown that statins have pleiotropic effects of anti-inflammatory action, antioxidant effect, antithrombotic action and facilitation of clot lysis, endothelial nitric oxide synthetase upregulation, plaque stabilization, low-density lipoprotein (LDL) oxidation reduction, and angiogenesis \[[@b1-jos-17-3-282]-[@b8-jos-17-3-282]\]. These pleiotropic effects potentially benefit in acute ischemia of the brain and heart. In addition, animal experiments have shown angiogenesis, neurogenesis, and synaptogenesis in acute cerebral ischemia \[[@b9-jos-17-3-282]\]. Thereby, statins are potentially neurorestorative as well as neuroprotective in acute cerebral ischemia.

In patients with acute coronary syndrome acute coronary syndrome or undergoing percutaneous coronary intervention, large observational studies, RCTs, and meta-analyses showed that statins improved the outcome \[[@b10-jos-17-3-282]-[@b17-jos-17-3-282]\]. Reflecting these evidences, the current cardiology guidelines recommend that 1) for patients with acute coronary syndrome, high-intensity statin therapy should be initiated or continued in all patients with ST elevation myocardial infarction and no contraindications (Class I; Level of Evidence B) \[[@b18-jos-17-3-282]\], 2) statins, in the absence of contraindications, regardless of baseline LDL-C and diet modification, should be given to post-unstable angina/non-ST elevation myocardial infarction patients, including postrevascularization patients. (Class I; Level of Evidence A) \[[@b19-jos-17-3-282]\], and 3) for patients undergoing percutaneous coronary intervention, administration of a high-dose statin is reasonable before percutaneous coronary intervention to reduce the risk of periprocedural MI (Class IIa; Level of Evidence A for statin naïve patients and LOE B for those on chronic statin therapy) \[[@b20-jos-17-3-282]\].

Despite the anticipated benefit of statins in acute ischemic stroke (AIS), no large randomized trial has been conducted as in acute coronary syndrome. The current systematic review aims to systematically review the statin effect in AIS.

Methods
=======

Using search terms of acute stroke and statin, 2,510 abstracts published until 31 December 2014 (including Epub ahead of print) were identified from PubMed search and reviewed by one author (Hong KS.). Then, we selected articles of human beings and AIS written in English. Manual review of references in articles identified 4 additional articles. As a results, the current systematic review included 70 articles: 30 articles of prestroke statin effect, 11 of in-hospital statin effect, 4 of statin withdrawal effect, 17 of statin effect in patients treated with thrombolysis, 8 of RCTs, 4 of prestroke statin effect on poststroke infection, and 7 studies with imaging surrogate markers (11 articles overlapped) ([Figure 1](#f1-jos-17-3-282){ref-type="fig"}).

For a descriptive overview, we tabulated articles according to each subject. If plausible, we conducted meta-analysis to estimate a pooled effect of statin effect in AIS. For this meta-analysis, only the original publications (excluding meta-analysis articles), which provided relevant odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI), were included. We did not contact authors of studies to request incomplete or unpublished data. To generate a pooled-estimate using a random-effect model, we used multivariable adjusted ORs or HRs and 95% CIs. However, if adjusted ORs were not provided, unadjusted ORs were used in limited cases (1 study for prestroke statin effect on functional outcome, 2 studies for prestroke statin effect on mortality, 2 studies for prestroke statin effect on initial stroke severity, 1 study for prestroke statin effect on mortality in patients with thrombolysis, and 1 study for statin effect on post-stroke infection).

We explored for sources of inconsistency (I^2^) and heterogeneity. Heterogeneity was assessed by the *P* value of χ^2^ statistics and by the I^2^ statistics. Heterogeneity was considered significant if the *P* value of χ^2^ statistics was \<0.10. For I^2^ statistics, we regarded I^2^ of \<40% as minimal, 40%-75% as modest, and \>75% as substantial \[[@b21-jos-17-3-282]\]. Publication bias was assessed graphically with a funnel plot and statistically with the Begg's test when 5 or more studies were available.

Results
=======

Imaging surrogate marker studies
--------------------------------

We identified 7 studies of prestroke statin effect on imaging surrogate markers in AIS: collaterals on conventional or CT angiography in 4, infarction volume on diffusion-weighted image (DWI) in 2, and reperfusion on perfusion MRI in 1 study ([Table 1](#t1-jos-17-3-282){ref-type="table"}) \[[@b22-jos-17-3-282]-[@b28-jos-17-3-282]\]. Among the 4 studies assessing collaterals in patients with acute large artery occlusion within 8 to 12 hours \[[@b23-jos-17-3-282],[@b26-jos-17-3-282]-[@b28-jos-17-3-282]\], 1 CT-based study showed that prestroke statin was associated with less collaterals \[[@b27-jos-17-3-282]\]. However, on the contrary, 3 conventional angiography-based studies showed that prestroke statin use was associated with more collaterals \[[@b23-jos-17-3-282],[@b26-jos-17-3-282],[@b28-jos-17-3-282]\]. Statin might enhance collaterals by inducing endothelial nitric oxide synthase activity and angiogenesis as shown in human coronary arteries \[[@b1-jos-17-3-282],[@b2-jos-17-3-282],[@b4-jos-17-3-282],[@b29-jos-17-3-282]\].

Prestroke statin effect on infarction volume was inconsistent across the 2 studies. In 1 study undergoing DWI evaluation within 48 hour (median time, 24 hours) of onset in patients with non-lacunar middle cerebral artery territory infarct, the prestroke statin group versus the no statin group had a significantly smaller infarct volume (median volume, 25.4 cm^3^ vs. 15.5 cm^3^, *P*=0.033 after adjusting covariates) \[[@b22-jos-17-3-282]\]. In another study, prestroke statin was not associated with infarction volume \[[@b24-jos-17-3-282]\]. However, the latter study had major limitations in that about 45% of patients had lacunar infarction and less than 40% performed DWI within 24 hours \[[@b24-jos-17-3-282]\].

In 1 small study (n = 31) which performed serial perfusion MRIs within 4.5 hours and at 6 hours after stroke onset, prestroke statin use was associated with 2- to 3-fold greater early reperfusion in all patients as well as subgroup of intravenous tissue plasminogen activator (IV-TPA) treated patients (74%) \[[@b25-jos-17-3-282]\]. Statin effect of enhancing collaterals, antithrombotic effect, and facilitating fibrinolysis might lead to better early reperfusion in acute cerebral ischemia \[[@b1-jos-17-3-282],[@b3-jos-17-3-282],[@b5-jos-17-3-282]\].

Prestroke statin effect in acute ischemic stroke
------------------------------------------------

We identified 30 articles (28 original articles, 3 meta-analyses, and 1 article providing both original data and meta-analysis findings) evaluating prestroke statin effect on initial stroke severity, functional outcome or short-term mortality ([Table 2](#t2-jos-17-3-282){ref-type="table"}) \[[@b30-jos-17-3-282]-[@b59-jos-17-3-282]\].

Prestroke statin effect on initial stroke severity
--------------------------------------------------

Seventeen original articles were identified and summarized in [Table 2](#t2-jos-17-3-282){ref-type="table"}. Most studies used the NIHSS score to measure initial stroke severity except for 3 studies, but the employed analytic methods were highly variable across studies, comparing median NIHSS scores or proportion of mild stroke with variable thresholds. In 3 of the 17 studies, prestroke statin was significantly associated with milder initial stroke severity or higher proportion of mild stroke \[[@b42-jos-17-3-282],[@b48-jos-17-3-282],[@b56-jos-17-3-282]\]. Seven studies provided ORs with 95% CI (adjusted ORs in 5 studies and unadjusted ORs in 2 studies) \[[@b34-jos-17-3-282],[@b38-jos-17-3-282],[@b41-jos-17-3-282],[@b46-jos-17-3-282],[@b53-jos-17-3-282],[@b55-jos-17-3-282],[@b56-jos-17-3-282]\]. Pooling 7 studies involving 6,806 patients showed that prestroke statin use was associated with milder stroke severity at stroke onset (OR, 1.24; 95% CI, 1.05-1.48; P= 0.013). Heterogeneity across studies was not found (*P*= 0.63, I^2^=0%) ([Figure 2A](#f2-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.322) ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). Pooling 5 studies providing adjusted ORs also showed a significant prestroke statin effect on initial stroke severity (OR, 1.24; 95% CI, 1.04-1.48; *P*=0.018) ([Supplemental Figure 2](#SD2){ref-type="supplementary-material"}).

Prestroke statin effect on functional outcome
---------------------------------------------

Three meta-analyses (outcome at 90 days outcome in 2 studies and discharge or 90 days in 1 study) \[[@b49-jos-17-3-282],[@b58-jos-17-3-282],[@b59-jos-17-3-282]\] and 21 original articles (outcome at discharge or 7-10 days in 14 studies and at 90 days in 7 studies) \[[@b30-jos-17-3-282]-[@b33-jos-17-3-282],[@b35-jos-17-3-282],[@b39-jos-17-3-282]-[@b49-jos-17-3-282],[@b51-jos-17-3-282],[@b54-jos-17-3-282],[@b55-jos-17-3-282],[@b57-jos-17-3-282]\] were identified and summarized in [Table 2](#t2-jos-17-3-282){ref-type="table"}. For functional outcome endpoint, modified Rankin Scale (mRS) 0-2 was most widely employed as a good outcome (12 studies: 10 original articles and 2 meta-analyses). In 14 (12 original article and 2 meta-analyses) of the 24 studies, patients with prestroke statin were more likely to achieve good functional outcome. Pooling 19 original publications (involving 30,942 patien ts) \[[@b30-jos-17-3-282]-[@b33-jos-17-3-282],[@b35-jos-17-3-282],[@b39-jos-17-3-282],[@b41-jos-17-3-282]-[@b49-jos-17-3-282],[@b51-jos-17-3-282],[@b54-jos-17-3-282],[@b55-jos-17-3-282],[@b57-jos-17-3-282]\], which provided adjusted ORs (95% CI), showed that prestroke statin use was associated with good functional outcome (OR, 1.50; 95% CI, 1.29-1.75; *P*\<0.001). There was a significant and modest heterogeneity across the studies (*P*=0.002, I^2^=55%). However, the heterogeneity was related to the magnitude of effect rather than the direction of effect ([Figure 2B](#f2-jos-17-3-282){ref-type="fig"}). A significant publication bias was found (*P*=0.001), but it was mainly attributed to studies with relatively small sample sizes ([Supplemental Figure 3](#SD3){ref-type="supplementary-material"}). Regarding ischemic stroke subtypes, 1 meta-analysis showed that the association of prestroke statin use and good functional outcome was significant in patients with large artery atherosclerosis and small vessel occlusion, but not in cardioembolic stroke \[[@b49-jos-17-3-282]\].

Prestroke statin effect on short-term mortality
-----------------------------------------------

Two meta-analyses (90-day mortality) \[[@b58-jos-17-3-282],[@b59-jos-17-3-282]\] and 10 original articles (mortality at discharge in 3 studies, 20-30 days in 4 studies, 90 days in 2 studies, and 365 days in 1 study) \[[@b34-jos-17-3-282],[@b36-jos-17-3-282]-[@b38-jos-17-3-282],[@b45-jos-17-3-282],[@b47-jos-17-3-282],[@b50-jos-17-3-282],[@b52-jos-17-3-282],[@b53-jos-17-3-282],[@b56-jos-17-3-282]\] were identified and summarized in [Table 2](#t2-jos-17-3-282){ref-type="table"}. In 8 (6 original articles and 2 meta-analyses) of the 12 studies, patients with prestroke statin had a lower mortality. Pooling 5 original publications (involving 4,508 patients), which provided ORs with 95% CI (adjusted ORs in 3 studies \[[@b36-jos-17-3-282],[@b45-jos-17-3-282],[@b47-jos-17-3-282]\] and unadjusted ORs in 2 studies \[[@b34-jos-17-3-282],[@b38-jos-17-3-282]\]), showed that prestroke statin use was associated with lower mortality (OR, 0.42; 95% CI, 0.21-0.82; *P*=0.011). A significant and modest heterogeneity across the studies was found (*P*=0.03, I^2^=64%), but the treatment effect was in the same direction except for 1 study ([Figure 2C](#f2-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.624) ([Supplemental Figure 4](#SD4){ref-type="supplementary-material"}). Pooling 3 studies providing adjusted ORs also showed a significant association of prestroke statin use with reduced mortality (OR, 0.36; 95% CI, 0.18-0.70; *P*=0.003) ([Supplemental Figure 5](#SD5){ref-type="supplementary-material"}). Two studies (involving 13,488 patients) reported adjusted HRs instead of ORs \[[@b52-jos-17-3-282],[@b53-jos-17-3-282]\]. Pooling these 2 studies also showed that prestroke statin use was associated with lower mortality (HR, 0.85; 95% CI, 0.77-0.93; *P*=0.0003). There was no significant heterogeneity across the studies (*P*=0.36, I^2^=0%) ([Figure 2D](#f2-jos-17-3-282){ref-type="fig"}).

In-hospital statin effect in acute ischemic stroke
--------------------------------------------------

We identified 11 articles (10 original articles and 1 meta-analysis) that assessed the in-hospital statin effect on functional outcome or short-term mortality ([Table 3](#t3-jos-17-3-282){ref-type="table"}) \[[@b35-jos-17-3-282],[@b47-jos-17-3-282],[@b51-jos-17-3-282]-[@b53-jos-17-3-282],[@b57-jos-17-3-282],[@b59-jos-17-3-282]-[@b63-jos-17-3-282]\].

In-hospital statin effect on functional outcome
-----------------------------------------------

One meta-analysis (at discharge or 30 days) \[[@b59-jos-17-3-282]\] and 9 original articles (at discharge in 4 studies and at 90 days in 5 studies) \[[@b35-jos-17-3-282],[@b47-jos-17-3-282],[@b51-jos-17-3-282],[@b53-jos-17-3-282],[@b57-jos-17-3-282],[@b60-jos-17-3-282]-[@b63-jos-17-3-282]\] assessed the in-hospital statin effect on functional outcome ([Table 3](#t3-jos-17-3-282){ref-type="table"}). For functional outcome endpoint, mRS 0-2 outcome was most commonly used as a good functional outcome (in 7 studies: 6 original articles and 1 meta-analysis). In 7 (6 original article and 1 meta-analysis) of the 10 studies, patients with in-hospital statin had a better functional outcome. Pooling 8 studies (involving 37,153 patients) \[[@b35-jos-17-3-282],[@b47-jos-17-3-282],[@b51-jos-17-3-282],[@b53-jos-17-3-282],[@b57-jos-17-3-282],[@b61-jos-17-3-282]-[@b63-jos-17-3-282]\], which provided adjusted ORs (95% CI), showed that in-hospital statin use was associated with good functional outcome (OR, 1.31; 95% CI, 1.12-1.53; *P*=0.001). There was a significant and modest heterogeneity across the studies (*P*=0.005, I^2^=65%), but the treatment effect was generally in the same direction except for 1 study ([Figure 3A](#f3-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.322) ([Supplemental Figure 6](#SD6){ref-type="supplementary-material"}).

In-hospital statin effect on short-term mortality
-------------------------------------------------

One meta-analysis (at discharge or 30 days) and 6 original articles (at discharge in 2 studies, 90 days in 2 studies, and 365 days in 2 studies) assessed the in-hospital statin effect on shortterm mortality ([Table 3](#t3-jos-17-3-282){ref-type="table"}). Of the 7 studies, 6 studies (5 original article and 1 meta-analysis) showed that patients with in-hospital statin use had a significantly lower mortality, whereas 1 study reported non-significant increase in mortality with in-hospital statin use. Three original articles provided adjusted ORs with 95% CI, and pooling these 3 studies involving 20,681 patients showed that in-hospital statin use was associated with lower mortality (OR, 0.41; 95% CI, 0.29-0.58; *P*\<0.001). A non-significant and modest heterogeneity across the studies was found across the studies (*P*= 0.12, I^2^=53%) ([Figure 3B](#f3-jos-17-3-282){ref-type="fig"}). Three original articles provided adjusted HRs with 95% CI, and pooling these 3 studies involving 14,002 patients showed that in-hospital statin use was not significantly associated with lower mortality (HR, 0.62; 95% CI, 0.33-1.16; *P*=0.138). A significant and substantial heterogeneity across the studies was found (*P*=0.002, I^2^=84%) ([Figure 3C](#f3-jos-17-3-282){ref-type="fig"}).

Statin withdrawal effect in acute ischemic stroke
-------------------------------------------------

Statin withdrawal effect was tested in one RCT performed in a single center \[[@b64-jos-17-3-282]\], and explored in three observational studies ([Table 4](#t4-jos-17-3-282){ref-type="table"}) \[[@b51-jos-17-3-282],[@b52-jos-17-3-282],[@b55-jos-17-3-282]\]. Of 3 studies assessing functional outcome (adjusted ORs for 90-day mRS 3-6 outcome in one study and for poor discharge disposition in 2 studies) \[[@b51-jos-17-3-282],[@b55-jos-17-3-282],[@b64-jos-17-3-282]\], 2 studies showed that statin withdrawal was associated with poor outcome \[[@b51-jos-17-3-282],[@b64-jos-17-3-282]\]. Pooling the 3 studies involving 13,583 patients showed that statin withdrawal was associated with poor functional outcome (OR, 1.83; 95% CI, 1.01-3.30; *P*=0.045). A significant and modest heterogeneity across the studies was found (*P*=0.07, I^2^=63%) ([Figure 4](#f4-jos-17-3-282){ref-type="fig"}). In one study, statin withdrawal was associated with an increased risk of 1-year mortality (HR, 2.5; 95% CI, 2.1-2.9; *P*\<0.001) \[[@b52-jos-17-3-282]\].

Statin effect in patients with thrombolysis
-------------------------------------------

We identified 17 studies (15 original articles, 4 meta-analyses, and 2 article providing both original data and meta-analysis findings) exploring statin effect on functional outcome, mortality, or symptomatic hemorrhagic transformation (SHT) in patients with thrombolysis (IV-TPA only in 12 studies, intra-arterial thrombolysis \[IA\] only in 2 studies, and IV-TPA or IA in 3 studies) ([Table 5](#t5-jos-17-3-282){ref-type="table"}) \[[@b58-jos-17-3-282],[@b59-jos-17-3-282],[@b65-jos-17-3-282]-[@b79-jos-17-3-282]\].

Statin effect on functional outcome in patients with thrombolysis
-----------------------------------------------------------------

Fifteen studies (14 original articles, 3 meta-analyses, and 2 article providing both original data and meta-analysis findings) reported the statin effect on functional outcome \[[@b59-jos-17-3-282],[@b65-jos-17-3-282],[@b67-jos-17-3-282]-[@b74-jos-17-3-282],[@b76-jos-17-3-282]-[@b79-jos-17-3-282]\]. Good functional outcome was defined as mRS 0-1 in 6 studies and mRS 0-2 in 8 studies, and mix-up of variable criteria in 1 meta-analysis. In earlier 3 meta-analyses \[[@b59-jos-17-3-282],[@b73-jos-17-3-282],[@b75-jos-17-3-282]\], statin was not associated with good functional outcome, whereas 5 studies among the 14 original articles showed that statin was associated with good functional outcome \[[@b65-jos-17-3-282],[@b67-jos-17-3-282],[@b72-jos-17-3-282],[@b76-jos-17-3-282],[@b78-jos-17-3-282]\]. Pooling 11 original articles (involving 10,876 patients, 1 article providing 2 ORs for both statin before and after and statin after only) \[[@b65-jos-17-3-282],[@b67-jos-17-3-282],[@b69-jos-17-3-282]-[@b74-jos-17-3-282],[@b76-jos-17-3-282],[@b78-jos-17-3-282],[@b79-jos-17-3-282]\], which provided adjusted ORs with 95% CI, showed that statin use in patients treated with thrombolysis was associated with good functional outcome (OR, 1.44; 95% CI, 1.10-1.89; *P*=0.008). A significant and modest heterogeneity was found across the studies (*P*\<0.001, I^2^=67%), but the direction of treatment effect was generally consistent except for 2 studies ([Figure 5A](#f5-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.493) ([Supplemental Figure 7](#SD7){ref-type="supplementary-material"}).

Statin effect on mortality in patients with thrombolysis
--------------------------------------------------------

Statin effect on the 90-mortality in patients with thrombolysis was assessed in 2 meta-analyses and 6 original articles ([Table 5](#t5-jos-17-3-282){ref-type="table"}) \[[@b58-jos-17-3-282],[@b59-jos-17-3-282],[@b68-jos-17-3-282],[@b71-jos-17-3-282],[@b73-jos-17-3-282],[@b74-jos-17-3-282],[@b76-jos-17-3-282],[@b79-jos-17-3-282]\]. Among the 3 meta-analyses, 1 meta-analysis showed that statin use was associated with increased mortality \[[@b59-jos-17-3-282]\]. Of the 6 original articles, 1 study showed that, statin use was significantly associated with lower mortality \[[@b76-jos-17-3-282]\], but the other studies found no significant effect. Pooling 5 original articles (involving 8,237 patients) \[[@b71-jos-17-3-282],[@b73-jos-17-3-282],[@b74-jos-17-3-282],[@b76-jos-17-3-282],[@b79-jos-17-3-282]\], which provided ORs with 95% CI (adjusted OR in 4 studies and unadjusted OR in 1 study), showed that statin use in patients treated with thrombolysis neither increased nor decreased mortality (OR, 0.87; 95% CI, 0.58-1.32; *P*=0.518). A significant and modest heterogeneity across the studies was found (*P*=0.02, I^2^=65%) ([Figure 5B](#f5-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.142) ([Supplemental Figure 8](#SD8){ref-type="supplementary-material"}). Pooling 4 studies providing adjusted ORs also showed that statin use was not associated with mortality in patients with thrombolysis (OR, 0.77; 95% CI, 0.48-1.25; *P*=0.289) ([Supplemental Figure 9](#SD9){ref-type="supplementary-material"}).

Statin effect on symptomatic hemorrhagic transformation in patients with thrombolysis
-------------------------------------------------------------------------------------

Sixteen studies (15 original articles, 3 meta-analyses, and 2 article providing both original data and meta-analysis findings) reported the statin effect on SHT ([Table 5](#t5-jos-17-3-282){ref-type="table"}) \[[@b58-jos-17-3-282],[@b65-jos-17-3-282]-[@b79-jos-17-3-282]\]. In 2 \[[@b58-jos-17-3-282],[@b75-jos-17-3-282]\] of the 3 meta-analyses and 3 \[[@b68-jos-17-3-282],[@b72-jos-17-3-282],[@b78-jos-17-3-282]\] of the 15 original articles, statin use was associated with an increased risk of SHT. Pooling 9 original articles (involving 10,419 patients) \[[@b67-jos-17-3-282],[@b68-jos-17-3-282],[@b70-jos-17-3-282]-[@b74-jos-17-3-282],[@b76-jos-17-3-282],[@b78-jos-17-3-282]\], which provided adjusted ORs with 95% CI, showed that statin use in patients treated with thrombolysis was associated with an increased risk of SHT (OR, 1.63; 95% CI, 1.04-2.56; *P*=0.035). A significant and modest heterogeneity across the studies was found (*P*=0.003, I^2^=65%) ([Figure 5C](#f5-jos-17-3-282){ref-type="fig"}). There was no significant publication bias (*P*=0.655) ([Supplemental Figure 10](#SD10){ref-type="supplementary-material"}).

Statin effect on post-stroke infection
--------------------------------------

Since statins have immunomodulatory effect, several studies assessed the association of statin use with post-stroke infection. Among 4 studies \[[@b79-jos-17-3-282]-[@b82-jos-17-3-282]\], 1 study \[[@b79-jos-17-3-282]\] showed that post-stroke pneumonia was less frequent in patients with prestroke statin use among IV-TPA treated patients ([Table 6](#t6-jos-17-3-282){ref-type="table"}). Pooling 3 original articles (involving 2,638 patients) \[[@b79-jos-17-3-282],[@b80-jos-17-3-282],[@b82-jos-17-3-282]\], which provided ORs with 95% CI (adjusted OR in 2 studies and unadjusted OR in 1 study), showed that the effect of statin on post-stroke infection was not significant (OR, 0.91; 95% CI, 0.30-2.77; *P*=0.867). There was a significant and modest heterogeneity across the studies (*P*=0.03, I^2^=70%) ([Figure 6](#f6-jos-17-3-282){ref-type="fig"}). Pooling 2 studies providing adjusted ORs also showed that statin use was not associated with post-stroke infection (OR, 1.16; 95% CI, 0.07-18.87; *P*=0.916) ([Supplemental Figure 11](#SD11){ref-type="supplementary-material"}).

Randomized controlled trials
----------------------------

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study randomized patients at 1 to 6 months after stroke. Therefore, the trial results cannot be considered as a reliable guide for statin use in AIS. Literature search identified 6 RCTs (statin withdrawal effect on functional outcome in 1, statin effect on functional outcome in 1, recurrent stroke within 90 days in 1, early neurological improvement in 1, and surrogate markers in 2 studies) \[[@b64-jos-17-3-282],[@b83-jos-17-3-282]-[@b87-jos-17-3-282]\], and one meta-analysis ([Table 7](#t7-jos-17-3-282){ref-type="table"}) \[[@b88-jos-17-3-282]\]. In addition, one phase 1B dose-finding single arm trial using an adaptive design of increasing lovastatin up to 10 mg/kg/day assessed the safety of high-dose statin, which showed that the final model-based estimate of toxicity was 13% (95% CI 3%-28%) for a dose of 8 mg/kg/day \[[@b89-jos-17-3-282]\]. There has been no large RCT, and the sample sizes of the published RCTs were small (ranging between 33 and 392), not adequately powered to assess the statin effect in AIS.

Markers of Inflammation after Simvastatin in Ischemic Cortical Stroke (MISTICS) was a pilot, double-blind, randomized, multicenter clinical trial, comparing inflammatory biomarkers between simvastatin versus placebo in patients with cortical AIS \[[@b84-jos-17-3-282]\]. The trial failed to demonstrate the anti-inflammatory effect of statin in human stroke despite rapid and sustained reduction of total and LDL-C levels with simvastatin. For clinical endpoints, patients on simvastatin compared to those on placebo were more likely to achieve NIHSS improvement 4 or more at 3 days, but did not achieve better 90-day mRS outcome.

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) was a relatively large RCT comparing simvastatin 40 mg versus placebo in 392 patients with a transient ischemic attack or minor stroke within the previous 24 hours \[[@b83-jos-17-3-282]\]. Because of the slow enrollment rate, the trial was early terminated after enrolling only 392 patients and thereby substantially underpowered. The rate of the primary endpoint of recurrent stroke within 90 days was 10.6% for the simvastatin group versus 7.3% for the placebo group (relative risk \[RR\], 1.3; 95% CI, 0.7-2.4; *P*=0.64).

Although the benefit of early statin initiation in AIS has not been demonstrated in RCTs, the harmful effect of statin withdrawal was demonstrated in a small, single center, randomized trial \[[@b64-jos-17-3-282]\]. In the trial, 89 patients with prestroke statins and hemispheric ischemic stroke within 24 hours were randomized to either transient statin withdrawal for the first 3 days or to continuation of statin treatment with atorvastatin 20 mg daily. The withdrawal group versus the continuation group was more likely to have poor functional outcome at 90 days (mRS 3-6, primary endpoint) (60.0% vs. 39.0%; adjusted OR \[95% CI\], 4.66 \[1.46 to 14.91\]), to experience early neurological deterioration of worsening NIHSS score 4 or more (65.2% vs. 20.9%; adjusted OR \[95% CI\], 8.67 \[3.05 to 24.63\]), and to have a greater infarct volume increase between 4 and 7 days. Based on this trial results, the American Stroke Association guidelines recommend the continuation of statin therapy during the acute period among patients already taking statins at the time of ischemic stroke (Class IIa; LOE B). However, the American Stroke Association guidelines do not provide specific recommendations regarding when to start statins in AIS patients with no prior statin treatment \[[@b90-jos-17-3-282]\].

In a recent meta-analysis including 7 published and unpublished RCTs involving 431 patients with AIS or transient ischemic attack within 2 weeks, all-cause mortality did not differ between the statin and placebo groups (OR 1.51, 95% CI 0.60 to 3.81) \[[@b88-jos-17-3-282]\].

Discussion
==========

Our systematic review could not find the evidence of statin benefit in AIS from RCTs although a small RCT demonstrated the harm of statin withdrawal. The results from observational studies were inconsistent. However, our updated meta-analysis using available data from original publications suggests that 1) prestroke statin use might reduce stroke severity at stroke onset, functional disability, and short-term mortality, 2) immediate post-stroke statin treatment might reduce functional disability and short-term mortality, whereas statin withdrawal might lead to worse outcome, and 3) in patients treated with thrombolysis, statins might improve functional outcome despite of an increased risk of SHT.

Imaging surrogate maker studies would provide a proof-of-concept for potential mechanisms of statin benefit in AIS. In general, surrogate marker studies suggest that statin benefit might be mediated by more collaterals and better reperfusion in AIS, and the findings in human with AIS are consonant with animal experiment study findings of improved cerebral flow secondary to upregulation of endothelial nitric oxide synthase, enhanced fibrinolysis, and reducing infarct size with statin treatment \[[@b3-jos-17-3-282]-[@b5-jos-17-3-282]\].

Investigating the prestroke statin effect would be a useful approach to assess the neuroprotective effect of statins in AIS. However, an RCT testing prestroke statin effect is not practically feasible because it requires a tremendous sample size. Given the neuroprotective effect of statins from animal experiment studies and imaging surrogate marker studies in human stroke, prestroke statin might limit ischemic brain damage and lead to mild stroke severity, and this effect, in part, might contribute to the better functional outcome with prestroke statin use. However, most published articles failed to show that prestroke statin was associated with less severe stroke. Since the statin benefit would not be substantial, the small sample sizes of the most published articles might account for the negative results. Previously, no meta-analysis has explored this statin effect. In our meta-analysis including data from 6,806 patients, pre-stroke statin use was associated with a 1.24-fold greater odds of stroke with milder severity, suggesting statin's neuroprotective effect during acute cerebral ischemia in human. A recent Korean large retrospective study (n=8,340) using propensity score matching analysis showed that prestroke stroke use was associated with mild stroke severity at presentation \[[@b91-jos-17-3-282]\].

An earlier *post-hoc* analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study explored statin effect on functional outcome in patients with recurrent stroke (i.e., prestroke statin effect on recurrent stroke), which had an advantage of randomizing patients either to statin or placebo. The authors suggested that the outcome of recurrent ischemic cerebrovascular events might be improved among statin users as compared with patients on placebo. However, the result was significant for the overall cohort, including patients with event-free as well as those with recurrent stroke. The analysis restricted patients with recurrent ischemic stroke outcome did not show a significant benefit of statin on functional outcome \[[@b40-jos-17-3-282]\].

For the statin effect on functional outcome, 2 previous meta-analyses (patients included in functional outcome analysis: n=11,965 in one study by Biffi et al. \[[@b49-jos-17-3-282]\] and n = 17,152 in another by Ní Chróinín et al. \[[@b59-jos-17-3-282]\]) showed the association of prestroke statin use with good functional outcome. In accord with previous results, the finding of our updated meta-analysis including more patients (n=30,942) strongly suggests that prestroke statin use might improve functional outcome. It is unclear whether, in addition to neuroprotection during ischemia, statin's facilitation of recovery after stroke as shown in animal experiments \[[@b9-jos-17-3-282]\], leads to the better functional outcome. In a recent large observational study in Korea, even after adjusting initial stroke severity as well as other covariates, prestroke statin users compared to non-users were more likely to achieve good outcome (mRS 0-2 outcome) at discharge, suggesting statin's dual effect of neuroprotection and neurorestoration \[[@b91-jos-17-3-282]\].

Our updated meta-analyses showed that statin whether administered prior to stroke or immediately after stroke was associated with better survival, as observed in earlier meta-analyses \[[@b58-jos-17-3-282],[@b59-jos-17-3-282]\]. In addition to better functional outcome, preventing recurrent vascular event might account for the statin benefit of reducing short-term mortality. In a meta-analysis of 7 RCTs in patients with acute coronary syndrome, statin initiation during acute period was associated with reduced mortality \[[@b92-jos-17-3-282]\]. Therefore, statin therapy might have beneficial effect of reducing mortality in patients with acute ischemia in the brain as well as in the heart. In patients with recent acute coronary syndrome, high intensity statin versus moderate intensity statin had a greater benefit in reducing mortality \[[@b93-jos-17-3-282]\]. For patients with AIS, a large observational study showed that 1-year survival benefit with statin during AIS was greater with high-dose statins than with low-dose statins \[[@b52-jos-17-3-282]\]. However, there has been no evidence from RCTs.

Worse outcome with statin withdrawal in a small RCT might indirectly indicate the statin benefit in AIS \[[@b64-jos-17-3-282]\]. Supporting the RCT finding, a large observational study \[[@b51-jos-17-3-282]\] and our meta-analysis showed the harmful effect of statin withdrawal during AIS. In the RCT, statin withdrawal even for a brief period of 3 days led to early neurological deterioration and greater infarct volume increase as well as 90-day worse functional outcome. Therefore, the potential mechanisms might be related to, rather than LDL-lowering, pleiotropic effects on endothelial function, inflammation, platelet, and fibrinolytic system \[[@b1-jos-17-3-282],[@b3-jos-17-3-282]-[@b5-jos-17-3-282]\].

Statins have antithrombotic and fibrinolytic effects, and in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial patients on high-dose atorvastatin compared to those on placebo had more hemorrhagic strokes. Therefore, among neurologists, there has been concern on the increased risk of hemorrhagic transformation with statin use in AIS, particularly for patients treated with thrombolysis. The current meta-analysis showed that statin was associated with an increased risk of SHT after thrombolysis, as shown in a previous meta-analysis \[[@b58-jos-17-3-282]\]. However, despite the increased risk of SHT, the functional outcome was better with statin use in our meta-analysis, which was not observed in earlier meta-analyses \[[@b59-jos-17-3-282],[@b73-jos-17-3-282],[@b75-jos-17-3-282]\]. Therefore, prestroke statin use would not be a contraindication for thrombolysis. However, whether statin therapy should be initiated immediately after reperfusion therapy in AIS as in acute coronary syndrom needs to be tested with RCTs.

This study has several limitations. Our findings were almost exclusively driven from data of observational studies, which are at risk of bias. In most outcomes, we found a large amount of heterogeneity in the results among the included studies. However, in general, the heterogeneity was brought by the magnitude of effect rather than the direction of effect. For several outcomes, unadjusted ORs as well as adjusted ORs were combined to generate pooled estimates. However, unadjusted ORs used were from limited articles with relatively small sample sizes. Therefore, the effect on our findings was not substantial as shown in additional analyses pooling adjusted ORs only. The current study did not assess the statin effect on early recurrent stroke, which would be of interest of topics on future investigation. Finally, if the literature search fails to find out all relevant articles, the result of meta-analysis is at risk of bias. As we only searched PubMed, several relevant articles might be missed. However, to minimize this risk, we performed additional hand search by reviewing references listed in the included original publications and meta-analyses.

In conclusion, the current systematic review supports the benefit of statins in AIS. However, the findings were largely driven by observational studies, and thereby the benefit needs to be confirmed by well-designed, large RCTs.
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![Summary of study selection. ^\*^11 articles were overlapped. CEA, carotid endarterectomy; RCT, randomized controlled trial.](jos-17-3-282f1){#f1-jos-17-3-282}

![Association of prestroke statin use and initial stroke severity (A), good functional outcome (B), and short-term mortality (C, pooling studies providing OR; D, pooling studies providing HR). Values of OR or HR greater than 1.0 indicate that prestroke statin use was associated with milder initial stroke severity (A), good functional outcome (B), and higher risk of mortality (C and D). SE, standard error; IV, inverse variance; CI, confidence interval.](jos-17-3-282f2){#f2-jos-17-3-282}

![Association of in-hospital statin use and good functional outcome (A), and short-term mortality (B, pooling studies providing ORs; C, pooling studies providing HRs). Values of OR or HR greater than 1.0 indicate that in-hospital statin use was associated with good functional outcome (A), and higher risk of mortality (B and C). SE, standard error; IV, inverse variance; CI, confidence interval.](jos-17-3-282f3){#f3-jos-17-3-282}

![Association of statin withdrawal during hospitalization and poor functional outcome. Values of ORs greater than 1.0 indicate that statin withdrawal during hospitalization was associated with poor functional outcome. SE, standard error; IV, inverse variance; CI, confidence interval.](jos-17-3-282f4){#f4-jos-17-3-282}

![Association of statin use and good functional outcome (A), 90-day mortality (B), and symptomatic hemorrhagic transformation (C). Values of ORs than 1.0 indicate that statin use was associated with good functional outcome (A), higher risk of mortality (B), and higher risk of symptomatic hemorrhagic transformation (C). SE, standard error; IV, inverse variance; CI, confidence interval.](jos-17-3-282f5){#f5-jos-17-3-282}

![Association of statin use and post-stroke infection risk. Values of ORs greater than 1.0 indicate that statin use was associated with an increased risk of post-stroke infection. SE, standard error; IV, inverse variance; CI, confidence interval.](jos-17-3-282f6){#f6-jos-17-3-282}

###### 

Studies of pre-stroke statin effect on surrogate markers in acute ischemic stroke

  Study                                             Publication   N     Region             Center/design   Age   Women (%)   Stroke type                           Prestroke statin use (%)   Surrogates                       Findings
  ------------------------------------------------- ------------- ----- ------------------ --------------- ----- ----------- ------------------------------------- -------------------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------
  Shook et al.\[[@b22-jos-17-3-282]\]               2006          143   USA                Single          66    48          MCA infarction \< 48 hr               26.6                       DWI infarct volume               Smaller infarct volume: adjuste *P* = 0.033
  Ovbiagele et al. \[[@b23-jos-17-3-282]\]          2007          96    USA                Single          66    48          Acute LAO \< 8 hr                     19.8                       Collaterals, angiography-based   Higher collateral scores: adjusted *P* = 0.003
  Nicholas et al. \[[@b24-jos-17-3-282]\]           2008          285   USA                Single          NR    51          AIS                                   36.8                       DWI infarct volume               infarct volume less than median, non-significant among all patients, but higher with statin users among diabetes
  Ford et al. \[[@b25-jos-17-3-282]\]               2011          31    USA                Single          61    45          AIS \< 4.5 hr (74%, IV-TPA treated)   37.8                       Reperfusion on MRI               Greater reperfusion: adjusted *P* = 0.021
  Sargento-Freitas et al. \[[@b26-jos-17-3-282]\]   2012          118   Portugal           Single          70    45          Acute LAO with IA therapy             38.3                       Collaterals, angiography-based   More good collaterals: adjusted OR, 6.0 (1.34-26.81)
  Malik et al. \[[@b27-jos-17-3-282]\]              2014          82    Switzerland, USA   Multicenter     41    60          M1 occlusion \< 12 hr                 28.0                       Collaterals, CT-based            Less collaterals: adjusted *P* = 0.001
  Lee et al. \[[@b28-jos-17-3-282]\]                2014          98    South Korea, USA   Multicenter     71    62          M1 occlusion \< 12 hr+AF              22.4                       Collaterals, angiography-based   More excellent collaterals: adjusted OR, 7.84 (1.96-31.36)

###### 

Studies of prestroke statin effect in acute ischemic stroke

  Study                                                          Publication   N                                                               Region          Center/design               Age     Women (%)   Prestroke statin (%)   Effect on hitial stroke severity                                                                                           Time point             Effect on functional outcome                                                                                      Effect on mortality
  -------------------------------------------------------------- ------------- --------------------------------------------------------------- --------------- --------------------------- ------- ----------- ---------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Jonsson et al. \[[@b30-jos-17-3-282]\]                         2001          375                                                             Sweden          Population-based            66      26          33.3                   NR                                                                                                                         7 days                 Non-significant, discharge to home OR, 1.42 (0.90-2.22)                                                           NR
  Martí-Fàbregas et al. \[[@b31-jos-17-3-282]\]                  2004          167                                                             Spain           Multicenter                 71      44          18.0                   Non-significant, median NIHSS *P*=0.76 (unadjusted)                                                                        90 days                Significant, BI 95-100 OR, 5.55 (1.42-17.8)                                                                       NR
  Greisenegger et al. \[[@b32-jos-17-3-282]\]                    2004          1,691                                                           Austria         Population-based            71      47          9.0                    NR                                                                                                                         7 days                 Significant, mRS 0-4 OR, 2.27 (1.09-4.76)                                                                         NR
  Yoon et al. \[[@b33-jos-17-3-282]\]                            2004          433                                                             USA             Single                      75      52          21.9                   NR                                                                                                                         Discharge              Significant, mRS 0-1 OR, 2.9 (1.2-6.7)                                                                            NR
  Elkind et al. \[[@b34-jos-17-3-282]\]                          2005          650                                                             USA             Population-based            70      55          8.8                    Non-significant, proportion of NIHSS \<15 OR, 1.67(0.70-4.00)                                                              90 days                NR                                                                                                                Significant reduction Unadjusted OR, 0.13 (0.02-0.94)
  Moonis et al. \[[@b35-jos-17-3-282]\]                          2005          852                                                             International   RCT, post-hoc               68      48          15.1                   Non-significant, mean NIHSS NR, unadjusted                                                                                 90 days                Non-significant, mRS 0-2 OR, 1.03 (0.54-1.27)                                                                     NR
  Aslanyan et al. \[[@b36-jos-17-3-282]\]                        2005          615                                                             Scotland        Single                      68      52          33.3                   Non-significant, mean NIHSS *P*= 0.8 (unadjusted)                                                                          30 days                NR                                                                                                                Significant reduction OR, 0.24 (0.09-0.67)
  Bushnell et al. \[[@b37-jos-17-3-282]\]                        2006          217                                                             International   RCTs, post-hoc              NR      33          29.0                   Non-significant, CNS score unadjusted *P*=0.13                                                                             28 days                NR                                                                                                                Non-significant Unadjusted *P*=0.84
  Chitravas et al. \[[@b38-jos-17-3-282]\]                       2007          716                                                             Austria         Population-based            75      53          7.0                    Non-significant, proportion of NIHSS \<8 unadjusted OR, 0.69 (0.67-3.13); adjusted OR, NS                                  28 days                NR                                                                                                                Non-significant Unadjusted OR, 1.21 (0.53-2.78); adjusted OR, NS
  Reeves et al. \[[@b39-jos-17-3-282]\]                          2008          1,360                                                           USA             Multicenter                 NR      52          22.7                   NR                                                                                                                         Discharge              Non-significant, mRS 0-3 OR, 1.35 (0.98-1.89)                                                                     NR
  Goldstein et al. \[[@b40-jos-17-3-282]\]                       2009          412                                                             International   RCT, post-hoc               65      34          43.7                   NR                                                                                                                         90 days                Non-significant, mRS distribution *P*= 0.0647                                                                     NR
  Yu et al. \[[@b41-jos-17-3-282]\]                              2009          339                                                             Canada          Single                      73      48          21.8                   Non-significant, proportion of CNS \>7 OR, 1.29 (0.70-2.38)                                                                10 days                Significant, mRS 0-2 OR, 2.00 (1.00-4.00)                                                                         NR
  Martínez-Sánchez et al. \[[@b42-jos-17-3-282]\]                2009          2,742                                                           Spain           Single                      69      44          10.2                   Significant, Canadian Stroke Scale mean 7.39 vs. 7.16, *P*= 0.045                                                          Discharge              Significant, mRS 0-1 OR, 2.08 (1.39-3.10) for all, 2.79(1.33-5.84) for LAA, 2.28 (1.15-4.52) for SVO              NR
  Cuadrado-Godia et al. \[[@b43-jos-17-3-282]\]                  2009          591                                                             Spain           Single                      73      46          23.0                   NR                                                                                                                         90 days                Non-significant, mRS 0-2 OR, 2.56 (0.95-6.67)                                                                     NR
  Stead et al. \[[@b44-jos-17-3-282]\]                           2009          207                                                             USA             Single                      72      40          48.3                   Non-significant, median NIHSS *P*=0.183                                                                                    Discharge              Significant, mRS 0-2 Adjusted OR, 1.91 (1.05-3.47) (adjusted *P*\<0.0001)                                         NR
  Arboix et al. \[[@b45-jos-17-3-282]\]                          2010          2,082                                                           Spain           Single                      75      53          18.3                   NR                                                                                                                         Discharge              Significant, mRS 0-2 OR, 1.32 (1.01-1.73)                                                                         Significant reduction OR, 0.57 (0.36-0.89)
  Sacco et al. \[[@b46-jos-17-3-282]\]                           2011          2,529                                                           Italy           Multicenter                 71      43          9.1                    Non-significant, proportion of NIHSS \<8 OR, 1.10 (0.80-1.57)                                                              Discharge              Significant, mRS 0-2 OR, 1.57 (1.09-2.26)                                                                         NR
  Ní Chróinín et al. \[[@b47-jos-17-3-282]\]                     2011          445                                                             Ireland         Population-based            71      49          30.1                   Non-significant, median NIHSS 5 vs. 5                                                                                      90 days                Significant, mRS 0-2 OR, 2.21 (1.00-4.90)                                                                         Significant reduction OR, 0.23 (0.09-0.58)
  Tsai\[[@b48-jos-17-3-282]\]                                    2011          172                                                             Taiwan          Single                      65      37          25                     Significant, Lower MIHSS, but unadjusted                                                                                   90 days                Significant, mRS 0-2 OR, 4.82 (1.22-19.03)                                                                        NR
  Biffi et al. \[[@b49-jos-17-3-282]\]                           2011          893                                                             USA             Single                      66      40          14.1                   Non-significant, proportion of NIHSS \>8 *P*=0.39 (unadjusted)                                                             90 days                Non-significant, mRS 0-2 OR, 1.51 (0.94-2.44)                                                                     NR
  Hassan et al. \[[@b50-jos-17-3-282]\]                          2011          386                                                             Malaysia        Single                      64      38          29.3                   NR                                                                                                                         Discharge              NR                                                                                                                Significant reduction Unadjusted *P*= 0.013
  Flint et al. \[[@b51-jos-17-3-282]\],\[[@b52-jos-17-3-282]\]   2012          12,689                                                          USA             Multicenter                 75      53          29.5                   NR                                                                                                                         Discharge or 1 year    Significant, discharge to home OR 1.21 (1.11-1.32) at discharge                                                   Significant reduction at 1 year HR, 0.85 (0.79-0.93)
  Hjalmarsson et al. \[[@b53-jos-17-3-282]\]                     2012          799                                                             Sweden          Single                      78      52          22.9                   Non-significant, proportion of NIHSS \<8 OR, 1.32 (0.80-2.17)                                                              30 days                NR                                                                                                                Non-significant HR, 0.56 (0.23-1.33)
  Aboa-Eboulé et al. \[[@b54-jos-17-3-282]\]                     2013          953                                                             France          Multicenter                 75      56          13.3                   Non-significant, median NIHSS 4 vs.4                                                                                       Discharge              Non-significant, mRS distribution OR 0.76 (0.53-1.09)                                                             NR
  Phipps et al. \[[@b55-jos-17-3-282]\]                          2013          804                                                             USA             Single                      86      64          41.5                   Non-significant, proportion of NIHSS \<8 OR 1.08 (0.71-1.66)                                                               Discharge              Non-significant, in-hospital mortality/hospice OR, 1.08 (0.60-1.94)                                               NR
  Martínez-Sánchez et al.\[[@b56-jos-17-3-282]\]                 2013          969                                                             Spain           Single                      69      38          27.1                   Significant, NIHSS \<6 OR, 1.249 (0.915-1.703) for low-to moderate-dose statin, 2.501 (1.173-5.332) for high-dose statin   Discharge              Non-significant, mRS 0-2 OR, not provided                                                                         Non-significant OR, not provided
  Moonis et al. \[[@b57-jos-17-3-282]\]                          2014          1,618                                                           USA             Multicenter                 67      52          14.3                   NR                                                                                                                         Discharge              Significant, discharge to home OR, 1.67 (CI, 1.12-2.49)                                                           NR
  Cordenier et al. \[[@b58-jos-17-3-282]\]                       2011          1,179/9,337^[\*](#tfn1-jos-17-3-282){ref-type="table-fn"}^                      Meta-analysis, 11 studies   NR      NR          16.3                   NR                                                                                                                         Discharge or 90 days   Non-significant mRS 0-2 outcome OR, 1.01 (0.64-1.61) at 90 days                                                   Significant redcution at discharge OR, 0.56 (0.40-0.78)
  Biffi et al. \[[@b49-jos-17-3-282]\]                           2011          11,695                                                                          Meta-analysis, 12 studies   NR      NR          17.2                   NR                                                                                                                         discharge to 90 days   Significant, favorable outcome OR, 1.62 (1.39-1.88) for all, 2.01 (1.14-3.54) for LAA, 2.11 (1.32-3.39) for SVO   NR
  Ní Chróinín et al. \[[@b59-jos-17-3-282]\]                     2013          17,606/101,615^[\*](#tfn1-jos-17-3-282){ref-type="table-fn"}^                   Meta-analysis, 27 studies   64-76   33-61       4-48                   NR                                                                                                                         90 days                Significant, mRS 0-2 OR, 1.41 (1.29-1.55)                                                                         Significant reduction OR, 0.71 (0.62-0.82)

Provided ORs (95% CIs) are adjusted ORs otherwise indicated, and ORs from meta-analyses are pooled ORs.

Numerator for mRS outcome sample size and denominator for mortality outcome sample size.

###### 

Studies of in-hospital statin effect in acute ischemic stroke

  Study                                                      Publication   N                                                            Region          Center/design      Age    Women (%)   In-hospital statin use (%)   Time point              Effect on functional outcome                            Effect on mortality
  ---------------------------------------------------------- ------------- ------------------------------------------------------------ --------------- ------------------ ------ ----------- ---------------------------- ----------------------- ------------------------------------------------------- ---------------------------------------------------------
  Moonis et al. \[[@b35-jos-17-3-282]\]                      2005          852                                                          International   RCT, post-hoc      68     48          14.4                         90 days                 Significant, mRS 0-2 OR, 1.57 (1.04-2.38)               NR
  Ní Chróinín et al. \[[@b47-jos-17-3-282]\]                 2011          445                                                          Ireland         Population-based   71     49          71                           90 days                 Non-significant, mRS 0-2 OR, 1.88 (0.971-3.91)          Significant reduction OR, 0.19 (0.07-0.48)
  Hjalmarsson et al. \[[@b53-jos-17-3-282]\]                 2012          799                                                          Sweden          Single             78     52          60.9                         90 or 365 days          Significant, mRS 0-2 at 90 days OR, 2.09 (1.25-3.52)    Significant reduction at 365 days
  Tsai et al. \[[@b60-jos-17-3-282]\]                        2012          100                                                          Taiwan          Single             63     35          50                           90 days                 Non-significant, mRS 0-2 Data not shown                 NR
  Yeh et al. \[[@b61-jos-17-3-282]\]                         2012          514                                                          Taiwan          Single             74     52          23.5                         90 days                 Non-significant, mRS 0-2 OR, 0.81 (0.43-1.51)           Non-significant increase HR, 1.68 (0.79-3.56)
  Flint et al. \[[@b51-jos-17-3-282],[@b52-jos-17-3-282]\]   2012          12,689                                                       USA             Multicenter        75     53          49.6                         Discharge or 1 year     Significant, discharge to home OR, 1.18 (1.08-1.30)     Significant reduction at 1 year HR, 0.55 (0.50-0.61)
  Song et al. \[[@b62-jos-17-3-282]\]                        2014          7,455                                                        China           Multicenter        64     39          43.3                         Discharge or 3 months   Significant, mRS 0-2 OR, 1.05 (0.90-1.23) at 3 months   Significant reduction OR, 0.51 (0.38-0.67) at discharge
  Al-Khaled et al. \[[@b63-jos-17-3-282]\]                   2014          12,781                                                       Germany         Population-based   73     49          59                           Discharge               Significant, mRS 0-1 OR, 1.25 (1.11-1.43)               Significant reduction OR, 0.39 (0.29-0.52)
  Moonis et al. \[[@b57-jos-17-3-282]\]                      2014          1618                                                         USA             Multicenter        67     52          11.6                         Discharge               Significant, discharge to home OR, 2.63 (1.61-4.53)     NR
  Ní Chróinín et al. \[[@b59-jos-17-3-282]\]                 2013          4,066/5,083^[\*](#tfn2-jos-17-3-282){ref-type="table-fn"}^   Meta-analysis   5 studies          71.3   33-61       14-71                        Discharge or 30 days    Significant, mRS 0-2 OR, 1.9 (1.59-2.27)                Significant reduction OR, 0.15 (0.07-0.31)

Provided ORs (95% CIs) are adjusted ORs otherwise indicated, and ORs from meta-analyses are pooled ORs.

Numerator for mRS outcome sample size and denominator for mortality outcome sample size.

###### 

Studies of statin withdrawal effect in acute ischemic stroke

  Study                                                      Publication   N        Region   Center/design   Age   Women (%)   Stroke type   Statin withdrawal (%)   Time point            Effect on functional outcome Findings for functional outcome                                Effect on mortality Findings for mortality
  ---------------------------------------------------------- ------------- -------- -------- --------------- ----- ----------- ------------- ----------------------- --------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------
  Blanco et al. \[[@b64-jos-17-3-282]\]                      2007          89       Spain    Single/RCT      67    49          AIS           51.7                    90 days               mRS 3-6 OR, 4.66 (1.46, 14.91)                                                              NR
  Flint et al. \[[@b51-jos-17-3-282],[@b52-jos-17-3-282]\]   2012          12,689   USA      Multicenter     75    53          AIS           3.7                     Discharge or 1 year   Significant, discharge to rehab, nursing care, or death OR, 1.30 (1.06-1.59) at discharge   Significant increase at 1 year HR, 2.5 (2.1-2.9)
  Phipps et al. \[[@b55-jos-17-3-282]\]                      2013          804      USA      Single          86    64          AIS           NR                      Discharge             Non-significant, discharge to hospice or death OR, 1.90 (0.96-3.75)                         NR

Provided ORs (95% CIs) are adjusted ORs otherwise indicated.

###### 

Studies of statin in patients with thrombolysis

  Study                                                                       Publication                                      N                        Region                 Center        Age    Women (%)   NIHSS   Thrombolysis   Pre-stroke or in-hospital statin use (%)   Time point   Effect on functional or mortality outcome                                                             Effect on SHT
  --------------------------------------------------------------------------- ------------------------------------------------ ------------------------ ---------------------- ------------- ------ ----------- ------- -------------- ------------------------------------------ ------------ ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Alvarez-Sabín et al. \[[@b65-jos-17-3-282]\]                                2007                                             145                      Spain                  Single        72     48          17      IV-TPA         17.9                                       90 days      Significant, mRS 0-2 OR, 5.26 (1.48-18.72)                                                            Non-significant data not shown
  Bang et al. \[[@b66-jos-17-3-282]\]                                         2007                                             104                      USA                    Single        70     51          16      IV-TPA or IA   25                                                      NR                                                                                                    Non-significant *P*= 0.566
  Uyttenboogaart et al. \[[@b67-jos-17-3-282]\]                               2008                                             252                      Netherlands            Single        68     46          12      IV-TPA         12.3                                       90 days      Significant, mRS 0-2 OR, 0.70 (0.25-1.94)                                                             Non-significant OR, 0.99 (0.18-5.43)
  Meier et al. \[[@b68-jos-17-3-282]\]                                        2009                                             311                      Switzerland            Single        63     43          14      IA             17.7                                       90 days      Non-significant, mRS 0-2 (P= 0.728) Mortality (P= 0.861)                                              Significant, more any ICH OR, 2.70 (1.16-6.44)
  Restrepo et al. \[[@b69-jos-17-3-282]\]                                     2009                                             142                      USA                    Single        69     49          17      IA             14.8 (pre- and post-stroke)                90 days      Non-significant, mRS 0-1 OR, 3.22 (0.57-18.03)                                                        Non-significant Unadjusted OR, 1.1
  31.7 (post-stroke)                                                          Non-significant, mRS 0-1 OR, 2.091 (0.71-6.13)   NR                                                                                                                                                                                                                                                                    
  Miedema et al.\[[@b70-jos-17-3-282]\]                                       2010                                             476                      Netherlands            Single        69     46          13      IV-TPA         20.6                                       90 days      Non-significant, mRS 0-2 OR, 1.11 (0.61-2.01)                                                         Non-significant OR, 1.60 (0.57-4.37)
  Engelter et al. \[[@b71-jos-17-3-282]\]                                     2011                                             4,012                    Europe                 Multicenter   68     44          12.4    IV-TPA         22.9                                       90 days      Non-significant, mRS 0-1: OR, 0.89 (0.74-1.06) Mortality: unadjusted OR, 1.29 (0.86-1.94)             Non-significant R, 1.32 (0.94-1.85) for ECASS II, 1.16 (0.87-1.56) for NINDS
  Cappellari et al. \[[@b72-jos-17-3-282]\]                                   2011                                             178                      Italy                  Single        NR     42          NR      IV-TPA         24.2 (pre- and post-stroke)                90 days      Non-significant, mRS 0-2 *P*=NS                                                                       Significant, more SHT OR, 6.65 (1.58-29.12)
  35.4 (post-stroke)                                                          Significant, mRS 0-2 OR, 6.18 (1.43-26.62)       Non-significant *P*=NS                                                                                                                                                                                                                                                
  Meseguer et al. \[[@b73-jos-17-3-282]\]                                     2012                                             606                      France                 Single        67     43          13      IV-TPA or IA   24.8                                       90 days      Non-significant, mRS 0-1, 1.55 (0.99-2.44) Mortality 0.80 (0.43-1.46)                                 Non-significant OR, 0.57 (0.22-1.49)
  Rocco et al. \[[@b74-jos-17-3-282]\]                                        2012                                             1,066                    Germay                 Single        73     47          12      IV-TPA         20.5                                       90 days      Non-significant, mRS 0-1, 1.14 (0.76-1.73) Mortality 1.32 (0.82-2.10)                                 Non-significant OR, 1.18 (0.56-2.48)
  Martinez-Ramirez et al. \[[@b75-jos-17-3-282]\]                             2012                                             182                      Spain                  Single        68     46          14      IV-TPA         16.3                                       90 days      Non-significant, mRS 0-2 OR not provided                                                              Non-significant OR not provided
  Cappellari et al. \[[@b76-jos-17-3-282]\]                                   2013                                             2,072                    Italy                  Multicenter   67     42          12.6    IV-TPA         40.5                                       90 days      Significant, mRS 0-2, 1.63 (1.18-2.26) Mortality 0.48 (0.28-0.82)                                     Non-significant OR, 0.52 (0.20-1.34)
  Zhao et al. \[[@b77-jos-17-3-282]\]                                         2014                                             193                      China                  Single        65     36          8.8     IV-TPA         24.4                                       90 days      Non-significant, mRS 0-1 *P*=0.913 (unadjusted)                                                       Non-significant *P*=0.965 (unadjusted)
  Scheitz et al. \[[@b78-jos-17-3-282]\]                                      2014                                             1,446                    Germany, Switzerland   Multicenter   75     46          11      IV-TPA         21.9                                       90 days      Significant, mRS 0-2 OR, 1.80 (1.29-2.51)                                                             Significant, more SHT with medium- and high-dose statin OR, 2.4 (1.1-5.3) for medium and 5.3 (2.3-12.3) for high
  Scheitz et al. \[[@b79-jos-17-3-282]\]                                      2015                                             481                      Germany                Single        74     50          11      IV-TPA         17.2                                       90 days      Non-significant mRS 0-2, 1.22 (0.68-2.20) Mortality 0.64 (0.30-1.37)                                  Non-significant *P*=0.63 (unadjusted)
  Cordenier et al. \[[@b58-jos-17-3-282]\]                                    2011                                             1,039                    Meta-analysis          3 studies     NR     NR          NR      IV- or IA      18.5                                                    NR                                                                                                    Significant, more SHT OR: 2.34 (CI 1.31-4.17)
  Ní Chróinín et al.\[[@b59-jos-17-3-282]\]                                   2013                                             4,993                    Meta-analysis          5 studies     68.6   44          NR      IV-TPA         22.3                                       90 days      Non-significant, mRS 0-1 OR, 1.01 (0.88-1.15)                                                         NR
  Significant mortality increase OR, 1.25 (1.02-1.52)                                                                                                                                                                                                                                                                                                                                                
  Meseguer et al. \[[@b73-jos-17-3-282]\]                                     2012                                             6,263/6,899              Meta-analysis          11 studies    NR     NR          NR      IV-TPA or IA   22.1                                       Variable     Non-significant, favorable outcome OR, 0.99 (0.88-1.12)                                               Significant, more SHT OR, 1.55 (1.23-1.95)
  Non-significant for studies (n=5524) with adjustment OR, 1.31 (0.97-1.76)                                                                                                                                                                                                                                                                                                                          
  Martinez-Ramirez et al. \[[@b75-jos-17-3-282]\]                             2012                                             1,055/910                Meta-analysis          3 studies     NR     NR          NR      IV-TPA         18.4                                       90 days      Non-significant, mRS 0-2 and mortality mRS 0-2, OR, 1.09 (0.73-1.61); mortality OR, 1.32(0.84-2.07)   Significant, more SHT

Provided ORs (95% CIs) are adjusted ORs otherwise indicated, and ORs from meta-analyses are pooled ORs.

^\*^Numerator for mRS or mortality outcome sample size and denominator for SHT outcome sample size.

###### 

Studies of statin effect on post-stroke infection

  Study                                                 Publication   N       Region    Center/design   Age   Women (%)   Population        Prestroke statin use (%)   Effect on infection Findings
  ----------------------------------------------------- ------------- ------- --------- --------------- ----- ----------- ----------------- -------------------------- --------------------------------------------------
  Rodríguez de Antonio et al. \[[@b80-jos-17-3-282]\]   2011          2,045   Spain     Single          69    43          AIS               15.0                       Non-significant unadjusted OR, 0.89 (0.61-1.29)
  Rodríguez-Sanz et al. \[[@b81-jos-17-3-282]\]         2013          1,385   Spain     Single          68    40          AIS               26.5                       Non-significant OR not provided
  Becker et al. \[[@b82-jos-17-3-282]\]                 2013          112     USA       Single          57    35          AIS               70.5                       Non-significant OR, 5.37 (0.81-35.37)
  Scheitz et al. \[[@b79-jos-17-3-282]\]                2015          481     Germany   Single          74    50          AIS with IV-TPA   17.3                       Significant, less pneumonia OR, 0.31 (0.10-0.94)

###### 

Clinical trials of statin in acute ischemic stroke

  RCT                                        Publication   N     Region          Center/design                   Intervention                            Stroke type                 Interval    Age   Women (%)   NIHSS   Primary endpoint                  Primary endpoint Finding                                      Effect on functional outcome                                      Effect on mortality                    DRE                                                 ICH
  ------------------------------------------ ------------- ----- --------------- ------------------------------- --------------------------------------- --------------------------- ----------- ----- ----------- ------- --------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------- --------------------------------------------------- -----------------
  Blanco et al. \[[@b64-jos-17-3-282]\]      2007          89    Spain           Single                          Statin withdrawal for 3 days            AIS with prestroke statin   \<24 hr     67    49          13      mRS 3-6 at 3 months               Significant                                                   Significant more mRS 3-6 with withdrawal OR, 4.66 (1.46, 14.91)   NR                                     NR                                                  NR
  FASTER \[[@b83-jos-17-3-282]\]             2007          392   International   Multicenter                     Simvastath 40 mg/day                    AIS                         \<24 hr     68    47          NR      Recurrent stroke within 90 days   Non-significant                                               NR                                                                NR                                     Non-significant for myositis or LFT abnormality     NR
  MISTICS \[[@b84-jos-17-3-282]\]            2008          60    Spain           Multicenter, single arm trial   Simvasatin 40 mg/day                    AIS                         3-12 hr     73    48          12      Inflammatory biomarkers           Non-significant                                               Non-significant, mRS distribution at 90 days *P*=0.86             Non-significant data not shown         More infection                                      NR
  NeuSTART \[[@b89-jos-17-3-282]\]           2009          33    USA             Multicenter, single arm trial   Lovastatin, 1-10 mg/kg/day for 3 days   AIS                         \<24 hr     62    52          5       Muscle or hepatotoxicity          Estimated toxicity of 13% at 8 mg/kg/day                      NR                                                                NR                                     Estimated toxicity of 13% at 8 mg/kg/day            NR
  Muscari et al. \[[@b85-jos-17-3-282]\]     2011          62    Italy           Single                          Aton/astatin 80 mg/day                  AIS                         \<24 hr     75    68          12.5    NIHSS improvement ≥4 at 7 days    Non-significant, *P*=0.59                                     Non-significant, mRS 0-1 at 90 days OR, 4.2 (0.8-22.3)            Non-significant 6.5% vs. 6.5%          Non-significant except for more LFT abnormalities   Non-significant
  Beer et al. \[[@b86-jos-17-3-282]\]        2012          40    Australia       Multicenter                     Aton/astatin 80 mg/day                  AIS                         \<96 hr     69    29          7       Infarct size at days 3 and 30     Non-significant, *P*=0.786 at 3 days and P=0.630 at 30 days   NR                                                                NR                                     NR                                                  NR
  Zare et al. \[[@b87-jos-17-3-282]\]        2012          55    Iran            Single                          Lovastatin, 20 mg/day                   MCA infarction              NR          66    47          15      Not specified                                                                                   Non-significant, BI at 90 days *P*=0.22                           Non-significant at 90 days *P*=0.26    NR                                                  NR
  Squizzato et al. \[[@b88-jos-17-3-282]\]   2011          431   Meta-analysis   7 studies                       Statins                                 AIS                         \<2 weeks   NR    NR          NR                                                                                                      NR                                                                Non-significant OR, 1.51 (0.60-3.81)   Can not be estimated                                NR

Provided ORs (95% CIs) are adjusted ORs otherwise indicated, and ORs from meta-analyses are pooled ORs.
